Please provide your email address to receive an email when new articles are posted on . Higher end-of-treatment hepatitis B surface antigen level correlated with nucleos(t)ide clinical relapse among ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ...
High preoperative HBsAg levels are associated with increased recurrence risk after curative resection for HBV-related HCC.
Please provide your email address to receive an email when new articles are posted on . Among patients with low baseline HBsAg, 39% achieved HBsAg loss with tobevibart/elebsiran, which rose to 46% ...
Background. With use of peginterferon alfa-2a and ribavirin combination therapy in patients with dual chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, 11.2% of patients achieved ...
OXFORD, United Kingdom, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), today announced the most significant data so far from the ongoing Phase 2b HBV003 clinical trial ...
ARC-520 achieves significant HBV s-Antigen (HBsAg) reductions in humans, particularly in treatment naïve, HBeAg-positive patients In a cohort of NUC-naïve, HBeAg-positive patients, best peak HBsAg ...
Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and disease progression, and could benefit from early antiviral treatment ...
Chronic hepatitis D coinfection affects an estimated 12 million people globally, with higher prevalence in low-income and middle-income countries, especially the African and Western Pacific regions.
As outlined in Table 1, the new PCO recommends that when HBV screening is pursued, both HB surface antigen (HBsAg) and HB core antibody (anti-HBc) be tested. 10 It also recommends against screening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results